ÂÜÀòÂÒÂ×

Yingying Chen has a diverse and extensive work experience in the finance and healthcare sectors. Yingying currently serves as the Chief Financial Officer at HARBOUR BIOMED since 2021. Prior to this role, they worked as the Managing Director and Head of Healthcare Investments at both GF Investments (HK) from 2016 to 2021 and China Minsheng International from 2014 to 2016.

Before transitioning into the investment field, Chen held key positions in investment banking, including serving as the Head of Healthcare Investment Banking at Deutsche Bank from 2011 to 2013 and as a Vice President of Investment Banking at Royal Bank of Scotland from 2010 to 2011. Yingying also had an Associate Director position at UBS in healthcare investment banking from 2005 to 2010.

Chen began their career in the healthcare industry as a Research Scientist at Pfizer from 2000 to 2003. Overall, they bring a strong background and expertise in finance and healthcare, showcasing their ability to excel in leadership roles and make strategic investment decisions.

Yingying Chen has pursued higher education in various prestigious institutions. Yingying holds a Bachelor of Science (BS) degree from Miami University. Additionally, Yingying Chen has completed their MBA from the University of Michigan - Stephen M. Ross School of Business. Yingying has also obtained a PhD from the University of Minnesota. The specific field of study for each degree is not provided.